Skip to main content
Premium Trial:

Request an Annual Quote

Schott Glass Technologies, Nanosphere, Nanogen, Illumina

Premium

Schott Glass Technologies to Collaborate on Microarrays with Israel’s Glycominds

Earlier this summer, Schott Glass Technologies of Germany was awarded a $1 million grant for DNA-related research the company is conducting at its Duryea, Pa., facility. The money comes from the BIRD Foundation (Binational Industrial Research and Development), established by the US and Israeli governments to fund industrial research beneficial to both countries.

Schott Glass, a wholly owned subsidiary of the German company, Schott Group, will produce microarrays in conjunction with Glycominds, of Lod, Israel.

The collaboration with Glycominds will initially focus on the development of high-throughput biochip technology for analysis of essential biological interactions mediated by glycans.

Schott Glass has previously announced a 4-year plan to enter the microarray industry with plans to hire as many as 200 scientists, engineers, and staffers.

 

Government Contract for Nanosphere

Nanosphere of Northbrook, Ill., last week announced a contract with the US Government Technical Support Working Group (TSWG) to apply its technology to the detection of biological warfare agents in various mediums. Financial terms of the contract were not disclosed.

Nanosphere said it will begin to redesign its current platform to create a field-deployable detection system to test water samples. The system will analyze water samples for signature nucleic acid sequences.

 

Nanogen in Epilepsy Diagnostic Deal

Nanogen and Bionomics Limited of Adelaide, Australia, last week announced an agreement to develop a diagnostic product for epilepsy.

Bionomics will license San Diego-based Nanogen’s NanoChip Molecular Biology Workstation with the goal of creating diagnostic tests. In return for support and funding, Nanogen will receive exclusive license to any diagnostic related intellectual property from the collaboration, the company said in a release.

 

NIH Awards Illumina $9 Million

Illumina announced last week that it has been awarded $9 million from the National Institutes of Health for large-scale genotyping aimed at understanding the widespread genetic variations that predispose individuals to common illnesses such as cancer and Alzheimer’s disease.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.